• +1-646-491-9876
    • +91-20-67278686

    Search

    Atypical Hemolytic Uremic Syndrome-Pipeline Review H2 2017

    Atypical Hemolytic Uremic Syndrome-Pipeline Review H2 2017

    • Report Code ID: RW0001881445
    • Category Life Sciences
    • No. of Pages 68
    • Publication Month Jul-17
    • Publisher Name Global Markets Direct
    Atypical Hemolytic Uremic Syndrome-Pipeline Review H2 2017

    Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Atypical Hemolytic Uremic Syndrome-Pipeline Review H2 2017 provides an overview of the Atypical Hemolytic Uremic Syndrome (Gastrointestinal) pipeline landscape.

    Atypical hemolytic uremic syndrome is a disease that primarily affects kidney function. This condition which can occur at any age causes abnormal blood clots (thrombi) to form in small blood vessels in the kidneys. Symptoms include vomiting abdominal pain pale skin tone fatigue and irritability blood in the urine and confusion.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Atypical Hemolytic Uremic Syndrome-Pipeline Review H2 2017 provides comprehensive information on the therapeutics under development for Atypical Hemolytic Uremic Syndrome (Gastrointestinal) complete with analysis by stage of development drug target mechanism of action (MoA) route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics its complete research and development history and latest news and press releases.

    The Atypical Hemolytic Uremic Syndrome (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes the molecules developed by Companies in Phase III Phase II Phase I Preclinical and Discovery stages are 2 2 2 1 and 1 respectively.

    Atypical Hemolytic Uremic Syndrome (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases company/university websites clinical trial registries conferences SEC filings investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Atypical Hemolytic Uremic Syndrome (Gastrointestinal) .
    - The pipeline guide reviews pipeline therapeutics for Atypical Hemolytic Uremic Syndrome (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise product description descriptive licensing and collaboration details R&D brief MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Atypical Hemolytic Uremic Syndrome (Gastrointestinal) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Atypical Hemolytic Uremic Syndrome (Gastrointestinal) therapeutics based on mechanism of action (MoA) drug target route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Atypical Hemolytic Uremic Syndrome (Gastrointestinal)

    Reasons to buy

    - Procure strategically important competitor information analysis and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Atypical Hemolytic Uremic Syndrome (Gastrointestinal) .
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Atypical Hemolytic Uremic Syndrome (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome)-Overview
    Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome)-Therapeutics Development
    Pipeline Overview
    Pipeline by Companies
    Products under Development by Companies
    Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome)-Therapeutics Assessment
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome)-Companies Involved in Therapeutics Development
    Achillion Pharmaceuticals Inc
    Akari Therapeutics Plc
    Alexion Pharmaceuticals Inc
    Amgen Inc
    ChemoCentryx Inc
    greenovation Biotech GmbH
    Kedrion SpA
    Omeros Corp
    Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome)-Drug Profiles
    ACH-4471-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    avacopan-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Complement Factor H Replacement for Atypical Hemolytic Uremic Syndrome-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Coversin-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    eculizumab biosimilar-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    GRN-003-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    OMS-721-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ravulizumab-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome)-Dormant Projects
    Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome)-Product Development Milestones
    Featured News & Press Releases
    Mar 27 2017 Omeros to Present Results from Dose-Ranging Stage of OMS721 Clinical Trial in Atypical Hemolytic Uremic Syndrome at World Congress of Nephrology
    Oct 27 2016 Alexion Initiates Simultaneous Registration Trials of ALXN1210 for Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) and Atypical Hemolytic Uremic Syndrome (aHUS)
    Oct 17 2016 ChemoCentryx Announces Presentation of Positive Data from Ongoing Pilot Phase II Trial of CCX168 (Avacopan) in Atypical Hemolytic Uremic Syndrome at ASN Kidney Week 2016
    Sep 06 2016 Achillion Presents Novel Research on Factor D Inhibition at the XXVIth International Complement Workshop
    Jul 28 2016 Omeros Confirms OMS721 Phase 3 Development Plan with European Medicines Agency
    May 23 2016 ChemoCentryx Announces Presentation of Positive Results from Phase II ANCA-Associated Vasculitis CLEAR Trial of Orally Administered Complement 5a Receptor Inhibitor CCX168 at the 53rd ERA-EDTA Congress
    Mar 08 2016 Omeros Initiates its Phase 3 Program for OMS721 in aHUS Following Meeting with FDA
    Jan 29 2016 Akari Therapeutics Receives Approval From the UK Medicines & Healthcare Products Regulatory Agency for Phase IB Multiple Ascending Dose Trial
    Jan 05 2016 Akari Therapeutics Announces Additional Data from Non-Human Primate Safety Study Demonstrating Equivalent Coversin Efficacy in Both Elisa CH50 and Hemolytic SRBC Assays
    Dec 07 2015 Akari Therapeutics Announces Update From Non-Human Primate Safety Study at International PNH Interest Group 10th Annual Scientific Meeting
    Dec 05 2015 Achillion Announces Upcoming Oral Presentation at the 57th Annual Meeting of the American Society of Hematology and Nomination of ACH-4471 a Novel Small Molecule Factor D Inhibitor for Clinical Development
    Nov 05 2015 ChemoCentryx Presents Phase II Results on CCX168 at the American Society of Nephrology Annual Meeting
    Aug 18 2015 Omeros Announces Additional Positive Data in OMS721 Phase 2 Clinical Trial
    Jul 23 2015 FDA Grants "Fast Track" to Omeros' Complement Inhibitor OMS721 for aHUS
    Apr 14 2015 European Regulatory Authority Approves Clinical Investigator's Request for Compassionate Use with Omeros Corporation's OMS721
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development for Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) H2 2017
    Number of Products under Development by Companies H2 2017
    Products under Development by Companies H2 2017
    Number of Products by Stage and Target H2 2017
    Number of Products by Stage and Mechanism of Action H2 2017
    Number of Products by Stage and Route of Administration H2 2017
    Number of Products by Stage and Molecule Type H2 2017
    Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome)-Pipeline by Achillion Pharmaceuticals Inc H2 2017
    Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome)-Pipeline by Akari Therapeutics Plc H2 2017
    Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome)-Pipeline by Alexion Pharmaceuticals Inc H2 2017
    Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome)-Pipeline by Amgen Inc H2 2017
    Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome)-Pipeline by ChemoCentryx Inc H2 2017
    Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome)-Pipeline by greenovation Biotech GmbH H2 2017
    Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome)-Pipeline by Kedrion SpA H2 2017
    Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome)-Pipeline by Omeros Corp H2 2017
    Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome)-Dormant Projects H2 2017

    List of Figures

    Number of Products under Development for Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) H2 2017
    Number of Products under Development by Companies H2 2017
    Number of Products by Targets H2 2017
    Number of Products by Stage and Targets H2 2017
    Number of Products by Mechanism of Actions H2 2017
    Number of Products by Stage and Mechanism of Actions H2 2017
    Number of Products by Routes of Administration H2 2017
    Number of Products by Stage and Routes of Administration H2 2017
    Number of Products by Molecule Types H2 2017
    Number of Products by Stage and Molecule Types H2 2017
    Achillion Pharmaceuticals Inc
    Akari Therapeutics Plc
    Alexion Pharmaceuticals Inc
    Amgen Inc
    ChemoCentryx Inc
    greenovation Biotech GmbH
    Kedrion SpA
    Omeros Corp

    Request for Sample

    Report Url https://www.reportsweb.com//atypical-hemolytic-uremic-syndrome-pipeline-review-h2-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url https://www.reportsweb.com//atypical-hemolytic-uremic-syndrome-pipeline-review-h2-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url https://www.reportsweb.com//atypical-hemolytic-uremic-syndrome-pipeline-review-h2-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments